On the other hand, the survivin ASO approach has shifted from preclinical investigations, where ASO treatment resulted in significant and stable protein expression inhibition both in SCC cell line and in xenograft nude mice models, to phase I trials in patients with advanced cancers. Here, BIRC5 is linked to cancer.